Диссертация (Совершенствование диспансерного наблюдения, лечения и медицинской реабилитации больных туберкулезом, сочетанным с ВИЧ-инфекцией), страница 36

et al. The growing burden oftuberculosis: global trends and interactions with the HIV epidemic. //Archives of Internal Medicine. – 2003. – 163:1009–1021.146. Dara M. et al. Guidelines for control of tuberculosis in prisons. Washington. –DC. – т USAID/TBCTA/ICRC. – 2009.147. De Colombani P. Overview of the tuberculosis situation in the EuropeanRegion with a focus on prisons. 11th Annual Meeting and Conference of theWorld Health Organization European Network for Prison and Health: theNext 10 Years. – London. – United Kingdom.

– 17-18 October 2005.148. Dheda K., Lampe F.C., Johnson M.A. et al. Outcome of HIV-associatedtuberculosisintheeraofhighlyactiveantiretroviral therapy. // J. Infect. Dis. – 2004. – Vol. 190. – № 9 . – P.1670-1676.149. Da Silva R.M., da Rosa L., Lemos R.N. Radiographic alterations in patients203presentinghumanimmunodeficiencyvirus/tuberculosiscoinfection:correlation with CD4+ T cell counts. // J. Bras. Pneumol. – 2006.

– Vol. 32. –№ 3. – P. 228-233.150. Diacon A.H. Combination therapy is just one emerging weapon in the fightagainst tuberculosis HIV-positive population. // Lancet. – 2012. – Vol. 487. –P. 14-21 (http://doi.org/h34).151. Diacon A.H. et al. 14-day bactericidal activity of PA-824, bedaquiline,pyrazinamide, and moxifloxacin combinations: a randomized trial. // Lancet2013; 380:986-93 (http://www.thelancet.com/journals/lancet/аrticle/PIIS01406736(12)61080-0/fulltext).152. Douek D.

HIV disease progression: immune activation, microbes, and a leakyg u t. / / Top HI V Med. – 2007. – Vol. 15. – № 4. – P. 114-117153. Drobniewski F.A. et al. Increasing trends in HIV and TB rates in Odessa andthe Ukraine. // International Journal of STD and AIDS. – 2005. – 16:374–378.154. Drobniewski F.A.

et al. Tuberculosis, HIV seroprevalence and intravenousdrugs abuse in prisoners. // European Respiratory Journal – 2005. – 26:298–304.155. Drug-Resistant Tuberculosis. A Survival Guide for Clinicians, 2nd edition. –2011. – Curry International Tuberculoses Center – University of CaliforniaSan Francisco. – 266 p(http://www.currytbcenter.ucsf.edu/drtb/drtb_ch3.cfm).156. Gandhi N.R. et al. Extensively drug-resistant tuberculosis as a cause of deathin patients co-infected with tuberculosis and HIV in a rural area of SouthAfrica.

// Lancet. – 2006. – 368:1575–1580.157. Girardi E., G. Antonucci G., Vanacore P. et al. Tuberculosis in HIV-infectedpersonsinthecontextofwideavailabilityofhighlyactive antiretroviral therapy. GISTA-SIMIT Study Group. // Eur. Respir. J. –2004. – Vol. 24. – № 1. – P. 11-17.158. Golub J.E. et al. The impact of antiretroviral therapy and isoniazid preventivetherapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro,Brazil.

// AIDS. – 2007. – 21:1441–1448.204159. Global tuberculosis control: WHO report. – 2013. – Geneva, World HealthOrganization. – 2011 (http://apps.who.int) /iris/bitstream/10665/44728/1/9789241564380_eng.pdf.160. Elliott A.M., Luzze H., Quigley M.A. et al. A randomized, double-blind,placebo-controlled trial of the use of prednisolone as an adjunct to treatmentin HIV-1-associated pleural tuberculosis. // J. Infect. Dis. – 2004.

– Vol. 190.– № 5 . – P. 869-878.161. Fletcher R., Fletcher R., Wagner E. (Флетчер Р., Флетчер С., Вагнер Э.).Клиническая эпидемиология: Основы доказательной медицины. (Пер. сангл.). – М. – 1998. – 347 с.162. Havlir D.V. et al. Opportunities and challenges for HIV care in overlappingHIV and TB epidemics. // JAMA. – 2008.

– 300:423–430.163. Heneghan C., Badenoch D. (Хенеган К., Баденоч Д.). Доказательнаямедицина (Пер. с англ.). – М. – 2011. – 125 с.164. Hoffmann C., Rockstroh J. K. (Хоффман К., Рокштро Ю. К.). ЛечениеВИЧ-инфекции. (Пер. с англ.). – М. – 2012. – 720 с.165. Holmes C.B. et al.

CD4 decline and incidence of opportunistic infections inCape Town, South Africa: implications for prophylaxis and treatment. //Journal of Acquired Immune Deficiency Syndromes. – 2006. – 42:464–469.166. Kingkaew N., Sangtong B., Amnuaiphon W.

et al. HIV-associatedextrapulmonary tuberculosis in Thailand: epidemiology and risk factors fordeath. // Int. J. Infect. Dis. – 2009. – Vol. 13. – № 6. – P. 722-729.167. Kirk O., Gatell J . M., Mocroft A.et al. Infections with Mycobacteriumtuberculosis and Mycobacterium avium among HIV-infected patients after theintroduction of highly active antiretroviral therapy. // Am. J. RespirCrit CareMed.

– 2000. – Vol. 162. – P. 865-872.168. Klautau G.B., Kuschnaroff Т.M. Clinical forms and outcome of tuberculosisi n HIV-infected patients in a tertiary hospital in Sao Paulo- Brazil. // Braz. J.Infect. Dis. – 2005. – Vol. 9. – № 6. – P. 464-478.169. Kwara A., Carter E.J . , Rich J.D. et al. // AIDS Patient Care STDS.

– 2004. –205Vol. 18. – № 6. – P. 341-347.170. Lawn S.D., Badri M, Wood R. Tuberculosis among HIV-infected patientsreceiving HAART: long term incidence and risk factors in a South Africancohort. // AIDS. – 2005. – 19:2109–2116.171. Lawn S.D. et al. Burden of tuberculosis in an antiretroviral treatmentprogrammed in sub-Saharan Africa: impact on treatment outcomes andimplications for tuberculosis control. // J. AIDS. – 2006. – 20:1605–1612.172. Li J., Munsiff S.S., Driver C.R.

et al. Relapse and acquired rifampinresistance in HIV-infected patients with tuberculosis treated with rifampin- orrifabutin-based regimens in New York City, 1997-2000. // Clin. Infect. Dis. –2005. – Vol. 41. – № l. – P. 83-91.173. Lopez-Cortes L.F., Marin-Niebla A., Lopez-Cortes L.E. et al. Influence oftreatment and immunological recovery on tuberculosis relapses in HIVinfected patients.

// I nt. J . Tuberc. Lung Dis. – 2005. – Vol. 9. – № 12. –P.1385-1390.174. Mermin J. et al. Mortality in HIV-infected Ugandan adults receivingantiretroviral treatment and survival of their HIV-uninfected children: aprospective cohort study. // Lancet. – 2008. – 371:752–759.175. Morozova I., Riekstina V., Holtz T. et al. Treatment outcomes for HIVinfected tuberculosis patients in Latvia, 1999-2004. // 16th Int.

Conf. AIDS. –Toronto. – Canada. – 2006. – Abstract no. MoPE0193.176. Nahid P., Daley C.L. Prevention of tuberculosis i n HIV-infected patients. //CurrOpin Infect. Dis. – 2006. – Vol. 19. – P. 18-193.177. Report on the global AIDS epidemic UN AIDS /08.25E / JC1510E // JointUnited Nations Programmed on HIV/AIDS (UN AIDS) 2008. – URL:(http://data.unaids.org/pub/GlobalReport/2008/jcl510_2008_global_reportj3pl_10_r u.pdf).178. Rocha M., Pereira S., Ferreira L.

et al. The role of adherence in tuberculosisHIV-positive patients treated in ambulatory regimen. // Eur. Respir. J. – 2003.– № 2 1 . – P. 785-788.206179. Ruiz-Navarro M.D., Espinosa J.A., Hernandez M.J. et al. Effects of HIVstatus and other variables on the outcome of tuberculosis treatment in Spain.Grupo de Trabajo del PMIT-2. // Arch. Bronconeumol. – 2005. – Vol.

41. –№ 7. – P. 363-370.180. Rustomjee R., Levin J.B., Onyebujoh P.C. et al. The effect of HIV coinfection on ТВ treatment outcomes. // 15th Int. Conf. AIDS. – Bangkok. –Thailand. – 2004. – Abstract no. MoPeB3220.181. Schiffer J.T., Sterling T.R. Timing of antiretroviral therapy initiation intuberculosis patients with AIDS: a decision analysis. // J. AIDS. – 2007. –Vol.

44. – P. 229-234.182. Selwyn P.A. et al. A prospective study of the risk of tuberculosis amongintravenous drug users with human immunodeficiency virus infection. // NewEngland Journal of Medicine. – 1989. – 320:545–550.183. Sonnenberg P. et al. How soon after infection with HIV does the risk oftuberculosis start to increase? a retrospective cohort study in South Africangold miners.

– Journal of Infectious Diseases. – 2005. – 191:150–158.184. Sterling T. et al. HIV-infection-related tuberculosis: clinical manifestationsand treatment. // Clinical Infectious Diseases. – 2010. – 50(Suppl. 3):S223–S230.185. Story A. et al. Tuberculosis in London: the importance of homelessness,problem drug use and prison. // Thorax, 2007, 62:667–671.186. Suchindran S., Brouwer E. S., Van Rie A. Is HIV Infection a Risk Factor forMulti-Drug Resistant Tuberculosis? A Systematic Review. // PLoS ONE. –2009. – т Vol. 4 .

– № 5 . – P. e55-e61.187. Swaminathan S., Deivanayagam C.N., Rajasekaran S. et al. Long term followu p of HIV-infected patients with tuberculosis treated with 6-monthintermittent short course chemotherapy. // Natl. Med. J India. – 2008. – Vol.21. – № 1. – P. 3-8.188. Tabarsi P., Baghaei P., Amiri M.et al. Treatment outcome of tuberculosispatients diagnosed with human immunodeficiency virus infection i n Iran. //20717th European Congress of Clinical Microbiology and Infectious Diseases. –Munich. – 2007.

– Abstract no. 17331114.189. Toma’s Tuberculosis. Case detection, treatment and monitoring – questionsand answers. Edited by T.Frieden. // WHO. – 2004. – 350 s.190. Treatment ofTuberculosis.Guidelines for National Programmers. . –WHO/TB. – Geneva – 1993. – 42 p.191. Treatment of tuberculosis guidelines. – 4th ed.

– WHO/HTM. – Geneva –2009 – 420 p.192. Туберкулез и ВИЧ-инфекция: ведение больных с коинфекцией.Клинический протокол для Европейского региона ВОЗ (обновленнаяверсия 2013 г.). (Пер. с англ.). – ВОЗ – 2013. – 52 с.193. Velasco M., Castilla V., Sanzet J. et al. Effect of simultaneous use of highlyactive antiretroviral therapy on survival of HIV patients with tuberculosis. // J.Acquir.

Immune. Defic. Syndr. – 2009. – Vol. 50. – № 2. – P.148-152.194. Wells C.D. et al. HIV infection and multidrug-resistant tuberculosis: theperfect storm. // Journal of Infectious Diseases. – 2007. – 196(Suppl. 1):S86–S107.195. Writing Committee for the CASCADE Collaboration et al. Timing ofHAART initiation and clinical outcomes in human immunodeficiency virustype 1 seroconverters.

// Archives of Internal Medicine. – 2011. – 171:1560–1569.208.